AZD3264 is a selective small-molecule inhibitor of IKK2 (IκB kinase 2), a key enzyme in the NF-κB signaling pathway that regulates inflammation and immune responses. It is primarily utilized in medical research for developing therapeutic agents targeting inflammatory and autoimmune diseases, such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). AZD3264 serves as a valuable tool in preclinical studies to investigate enzyme inhibition mechanisms, assess efficacy in modulating inflammatory pathways, and support early-stage drug discovery. While its development reached Phase II clinical trials, it has not progressed to approved therapies, making it a niche research compound rather than a commercial drug.